Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Safety and Efficacy of Utilizing CGRPmAb Fremanezumab (Ajovy) in Chronic Migraine Patients Currently on Monotherapy OnabotulinumtoxinA (Botox).

NCT05724771 is registered in ClinicalTrials.gov with Chicago Headache Center & Research Institute as lead sponsor.

NCT NCT05724771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05724771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Safety and Efficacy of Utilizing CGRPmAb Fremanezumab (Ajovy) in Chronic Migraine Patients Currently on Monotherapy OnabotulinumtoxinA (Botox).
Lead sponsor
Chicago Headache Center & Research Institute
Phase
Phase 4
Overall status
Active, not recruiting
Start date
January 26, 2023
Completion date
May 31, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine, headache